This trial showed that the combination of bortezomib
and KW-2478 was safe to use and could be a useful treatment for myeloma.
This trial recruited 79 people with myeloma which had either come back after treatment, or treatment hadn’t worked. Everyone taking part had both bortezomib and KW-2478.
The research team looked at how well the treatment worked. They found that the myeloma either went away or got better in 31 out of 79 people (39%). This is called the response rate. Other trials had shown that the response rate of bortezomib alone was about 35%.
They also looked at how long it was before the myeloma started to grow again. It was about 6.7 months. Other trials had shown similar results for people who had bortezomib alone.
74 of the people taking part had at least one side effect. Some of them were mild or didn’t last long, but 34 people had side effects that were more severe.
The most common of these more severe side effects were:
- tiredness (fatigue)
- a drop in white blood cells
- feeling sick
- a drop in blood clotting cells (platelets)
The research team concluded that the combination of bortezomib and KW-2478 was safe to use. And that it worked for some people whose myeloma had come back or not responded to other treatment. They suggest that KW-2478 is looked at in other trials, perhaps with different dosing or in combination with other treatments.
We have based this summary on information from the research team. The information they sent us has been reviewed by independent specialists (peer reviewed
) and published in a medical journal. The figures we quote above were provided by the trial team who did the research. We have not analysed the data ourselves.